Log in

Industry News Archive

FDA Approves Ponatinib Tablets for Adults with CP CML

Ponatinib (Iclusig, Takeda Oncology) is now now FDA-approved for the treatment of adult patients with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors. 

More information

Posted 1/5/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us